24R,25-dihydroxyvitamin D3 promotes bone formation without causing excessive resorption in hypophosphatemic mice

Area of Science:

• Endocrinology
• Bone Biology
• Mineral Metabolism

Background:

• Familial X-linked hypophosphatemic rickets is a genetic disorder characterized by impaired bone mineralization.
• Vitamin D metabolites play crucial roles in calcium and phosphate homeostasis and bone metabolism.
• Understanding the distinct actions of different vitamin D metabolites is essential for developing effective treatments.

Purpose of the Study:

• To compare the effects of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] and 24,25-(OH)2D3 on bone formation and resorption in hypophosphatemic (Hyp) mice.
• To elucidate the therapeutic potential of 24,25-(OH)2D3 in a mouse model of X-linked hypophosphatemic rickets.

Main Methods:

• Histomorphometric analysis of lumbar vertebrae in Hyp mice treated with varying doses of 1,25-(OH)2D3, 24,25-(OH)2D3, or vehicle.
• Assessment of bone formation parameters (mineralized bone volume, mineral apposition rate, bone formation rate) and bone resorption parameters (osteoclast number, osteoclast surface).

Main Results:

• Both 1,25-(OH)2D3 and 24,25-(OH)2D3 dose-dependently improved bone formation parameters in Hyp mice.
• 24,25-(OH)2D3 normalized bone resorption to control levels without excessive stimulation.
• 1,25-(OH)2D3 significantly increased bone resorption beyond control levels, indicating a potential adverse effect.

Conclusions:

• 24,25-(OH)2D3 demonstrates superior efficacy in improving bone lesions in Hyp mice compared to 1,25-(OH)2D3.
• The normalization of bone resorption by 24,25-(OH)2D3, alongside enhanced bone formation, highlights its therapeutic advantage.
• These findings suggest 24,25-(OH)2D3 as a promising therapeutic agent for hypophosphatemic rickets.